Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

February 7, 2026 updated by: Stanford University

Development of Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

The purpose of this study is to measure the levels of serum proteins and other biomarkers in cancer patients and in patients suspected of having cancer. We believe that some of these markers may be useful for confirming the diagnosis or for selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse after therapy, and survival after therapy.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Procedure: blood draw

Detailed Description

This is a blood serum collection study at Stanford University for patients with cancer at a variety of disease sites. The purpose of this study is to collect and store blood serum from patients before, during, and after anti-cancer therapy to find new biomarkers that signal disease or response to anti-cancer therapy. The collection and analysis of these biomarkers may lead to improved diagnostic and treatment therapies for certain cancers in the future. We are also interested in collecting blood serum from healthy individuals such as the spouses, relatives, and friends of cancer patients to obtain healthy controls for comparison

Study Type

Observational

Enrollment (Estimated)

2000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: gitrialeligibility@stanford.edu gitrialeligibility@stanford.edu
Phone Number: 650-498-7757
Email: gitrialeligibility@stanford.edu

Study Contact Backup

Name: gitrialeligibility@stanford.edu
Phone Number: 650-498-7757
Email: gitrialeligibility@stanford.edu

Study Locations

United States
- California
  - Stanford, California, United States, 94305
    - Recruiting
    - Stanford University School of Medicine
    - Principal Investigator:
      
      Maximilian Diehn
    - Contact:
      
      Rene Bonilla
      
      Phone Number: 650-498-7703
      
      Email: rbonilla@stanford.edu

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

cancer patients

Description

Age > or = 18; for the samples collected under the NIH grant, no subjects below the age of 20 will be enrolled.
Prior diagnosis of cancer or suspected of having cancer
Karnofsky performance status of greater than 70
Standard pretreatment evaluation
Signed Stanford University Human Subjects Committee consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Biomarkers for disease Time Frame: Day one	Day one

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Stanford University

Investigators

Principal Investigator: Maximilian Diehn, Stanford University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2002

Primary Completion (Estimated)

January 1, 2032

Study Completion (Estimated)

January 1, 2032

Study Registration Dates

First Submitted

July 5, 2006

First Submitted That Met QC Criteria